Clinical Trials Logo
  1. Home
  2. Rectal Cancer Stage III
  3. NCT04598984

The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer

Rectal Cancer Stage III Clinical Trial

Official title:
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer

Clinical Trial Summary

It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04598984
Study type Observational
Source Istanbul Training and Research Hospital
Contact Cihad Tatar, MD
Phone +905336599889
Email tatarcihad@gmail.com
Status Recruiting
Phase
Start date September 1, 2020
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT05495308 - "Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Active, not recruiting NCT04246684 - Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients Phase 3
Completed NCT05723965 - Using Artificial Intelligence to Predict Rectal Cancer Outcomes
Not yet recruiting NCT05830890 - Sentinel Lymph Node Biopsy in Rectal Cancer N/A
Active, not recruiting NCT04503694 - Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer Phase 2
Completed NCT02363374 - Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT03561142 - Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. Phase 2
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2
Recruiting NCT05148767 - UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer Phase 4
Recruiting NCT06254521 - The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer Phase 2
Completed NCT01325649 - Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma N/A
Recruiting NCT04970498 - Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Active, not recruiting NCT03840239 - TNT to Increase the Clinical Complete Response Rate for Distal LARC Phase 2
Active, not recruiting NCT03391843 - Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer Phase 2